HUP0301691A2 - Emlőseredetű 2. típusú szfingozin kináz izoalakok, továbbá klónozási, termeltetési és alkalmazási eljárásaik - Google Patents

Emlőseredetű 2. típusú szfingozin kináz izoalakok, továbbá klónozási, termeltetési és alkalmazási eljárásaik

Info

Publication number
HUP0301691A2
HUP0301691A2 HU0301691A HUP0301691A HUP0301691A2 HU P0301691 A2 HUP0301691 A2 HU P0301691A2 HU 0301691 A HU0301691 A HU 0301691A HU P0301691 A HUP0301691 A HU P0301691A HU P0301691 A2 HUP0301691 A2 HU P0301691A2
Authority
HU
Hungary
Prior art keywords
isoforms
sphingosine kinase
methods
type
cloning
Prior art date
Application number
HU0301691A
Other languages
English (en)
Inventor
Takafumi Kohama
Sarah Spiegel
Original Assignee
Sankyo Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co. Ltd. filed Critical Sankyo Co. Ltd.
Publication of HUP0301691A2 publication Critical patent/HUP0301691A2/hu
Publication of HUP0301691A3 publication Critical patent/HUP0301691A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgyát emlőseredetű (pl. egéreredetű vagy humán)szfingozin kináz 2. típusú izoalakjai, az ilyen izoalakok molekulárisklónozása, valamint az izoalakok alkalmazási eljárásai képezik. A 2.típusú szfingozin kináz az 1. típustól megkülönböztethetőtulajdonságokkal bír. A találmány szerinti megoldás alkalmas 2. típusúszfingozin kináz aktivitását befolyásoló hatóanyagok izolálására, éscsökkent mértékű sejthalállal vagy fokozott mértékűsejtproliferációval összefüggő rendellenességek kezelésére ésmegelőzésére. Ó
HU0301691A 2000-04-03 2001-03-26 Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use HUP0301691A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19431800P 2000-04-03 2000-04-03
US09/817,676 US6800470B2 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
PCT/US2001/009664 WO2001074837A1 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof

Publications (2)

Publication Number Publication Date
HUP0301691A2 true HUP0301691A2 (hu) 2003-08-28
HUP0301691A3 HUP0301691A3 (en) 2005-04-28

Family

ID=26889896

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301691A HUP0301691A3 (en) 2000-04-03 2001-03-26 Mammalian sphingosine kinase tipe 2 isoforms, cloning, expression and methods of use

Country Status (9)

Country Link
US (4) US6800470B2 (hu)
JP (1) JP4584525B2 (hu)
KR (1) KR20020093017A (hu)
AU (1) AU5100201A (hu)
CA (1) CA2404965A1 (hu)
DK (1) DK1268509T3 (hu)
HU (1) HUP0301691A3 (hu)
MX (1) MXPA02009781A (hu)
WO (1) WO2001074837A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404965A1 (en) * 2000-04-03 2001-10-11 Sankyo Company, Limited Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
JP2005522999A (ja) * 2002-01-31 2005-08-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 癌を処置するための方法および組成物
MXPA05003974A (es) * 2002-10-14 2005-08-03 Medvet Science Pty Ltd Un metodo de modulacion de la actividad celular epitelial mediante la modulacion de los niveles funcionales de la esfingosina cinasa.
WO2004061107A1 (ja) * 2002-12-27 2004-07-22 The New Industry Research Organization スフィンゴシンキナーゼ２を利用した細胞増殖抑制剤、その核移行シグナルを持つ融合タンパク質の作製方法、及び薬剤候補物質のスクリーニング方法、並びにスクリーニングキット
US8314151B2 (en) 2008-04-29 2012-11-20 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, and processes for using same
US8372888B2 (en) * 2008-04-29 2013-02-12 Enzo Therapeutics, Inc. Sphingosine kinase type 1 inhibitors, compositions and processes for using same
US10660879B2 (en) 2017-06-23 2020-05-26 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers
WO2018237379A2 (en) 2017-06-23 2018-12-27 Enzo Biochem, Inc. COMPOUNDS MODULATING THE PATH OF SPHINGOSINE FOR THE TREATMENT OF CANCERS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374616A (en) * 1991-10-18 1994-12-20 Georgetown University Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor
EP1235913A2 (en) * 1998-05-26 2002-09-04 Sarah Spiegel Sphingosine kinase, cloning, expression and methods of use
EP1257637A2 (en) * 2000-02-14 2002-11-20 Curagen Corporation Sphingosine kinases
CA2404965A1 (en) * 2000-04-03 2001-10-11 Sankyo Company, Limited Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof

Also Published As

Publication number Publication date
US8263349B2 (en) 2012-09-11
MXPA02009781A (es) 2004-09-06
DK1268509T3 (da) 2010-03-08
US20040203104A1 (en) 2004-10-14
WO2001074837A1 (en) 2001-10-11
HUP0301691A3 (en) 2005-04-28
US20120107833A1 (en) 2012-05-03
JP2004500117A (ja) 2004-01-08
KR20020093017A (ko) 2002-12-12
US7419814B2 (en) 2008-09-02
US7803595B2 (en) 2010-09-28
US20020042101A1 (en) 2002-04-11
US20090169555A1 (en) 2009-07-02
US6800470B2 (en) 2004-10-05
AU5100201A (en) 2001-10-15
CA2404965A1 (en) 2001-10-11
JP4584525B2 (ja) 2010-11-24

Similar Documents

Publication Publication Date Title
ATE296799T1 (de) P38-inhibitoren
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
ME00275B (me) ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
GEP20032954B (en) Heterocyclic Inhibitors of P38
MEP36908A (en) omega-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
MY117696A (en) INHIBITORS OF p38
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
MY133159A (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
DE69033020T2 (de) Kombinationstherapie zur prophylaxe und/oder behandlung benigner prostatahyperplasie
ATE293989T1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
UY26205A1 (es) Derivados de indoloxoacetil piperazina antiviricos
TR200100728T2 (tr) Botulinum toksininin stabil sıvı formülasyonları
HUP0301691A2 (hu) Emlőseredetű 2. típusú szfingozin kináz izoalakok, továbbá klónozási, termeltetési és alkalmazási eljárásaik
DE50007706D1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
ATE346147T1 (de) Zusammensetzungen und methoden zur wundheilung
DK1196598T3 (da) DSP-3 phosphatase med dobbelt specificitet
DE60323876D1 (de) Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE369129T1 (de) Kombination eines atp-competitiven inhibitors der bcr/abl kinase und eines tyrphostin analogen
NO20024727D0 (no) Pattedyr-sfingosinkinase-type 2-isoformer, kloning, ekspresjon og anvendelser derav
MY129421A (en) INHIBITORS OF p38